|  |
| --- |
|  |
| **Joint EMRO/TDR Small Grants Scheme****for Implementation Research in Communicable Diseases****2018-2019****Application Form** ***For official use only***  |
| Date of receipt [ / /2018] | Disease [ ] | ID No: [SGS18/ ] |
| **1.RESEARCH TEAM**  |  |
| **1.1 PRINCIPAL INVESTIGATOR** |  |
| Last name: | First name:  |
| Title and Affiliation: |  |
| Full postal address: | Gender: Male [ ] Female [ ] |
| Type of institution (Ministry of Health, National control programme, academic institution, NGO) |  |
| e-mail: |  |
| Sector:  | Public [ ] Private [ ] |
| Direct telephone number with country and city code:  |  |
| **1.2 CO-INVESTIGATORS** |  |
| Last name: | First name:  |
| Title and Affiliation: |  |
| Full postal address: | Gender: Male [ ] Female [ ] |
| Type of institution (Ministry of Health, National control programme, academic institution, NGO) |  |
| e-mail: |  |
| Sector:  | Public [ ] Private [ ] |
| Direct telephone number with country and city code:  |  |
| Add rows as needed |  |
| **2. RESEARCH PRIORITIES**  |
|

|  |  |  |  |
| --- | --- | --- | --- |
| **Disease**  | **Topic** | **Yes**  | **No** |
| **Tuberculosis**  | Evaluation of new models/interventions for implementation of ambulatory MDR-TB |  |  |
|  | Cost–effectiveness of new diagnostic tools for multiple drug resistance (MDR) detection in both public and private heath sectors  |  |  |
|  | Improving collaboration and reporting of TB cases with the private sector in high TB burden countries |  |  |
|  | Assessing catastrophic cost of TB diagnosis and management on families |  |  |
| **Malaria** | Plasmodium vivax burden in EMR endemic African countries |  |  |
|  | Improving access to malaria interventions, including surveillance for remote, migrant and mobile populations |  |  |
|  | Enhancing community engagement for implementation of vector control interventions, especially for remote and vulnerable populations |  |  |
|  | Assessing the burden of co-infection of malaria and Aedes-borne arboviral diseases |  |  |
| **Leishmaniasis** | Evaluating and comparing preventive measures to reduce/interrupt transmission of leishmaniasis  |  |  |
| **Leprosy** | Innovative approaches to increase detection of new cases of leprosy  |  |  |
| **Other Diseases** | Investigating determinants of transmission of schistosomiasis in hotspots in late stage of elimination |  |  |
| Innovative approaches for facial cleanliness and environmental improvement components of the SAFE[[1]](#footnote-1) strategy for trachoma elimination |  |  |
| Analysis study of the economic impact of hepatitis C prevention and treatment intervention scenarios |  |  |
| Integrated bio-behavioural surveys and population size estimates among key populations[[2]](#footnote-2) |  |  |
| Improving access to diagnostic and management tools for HIV, hepatitis B, C infections |  |  |
| Integrated use of multi-disease diagnostic devices for HIV, hepatitis B & C |  |  |
| Effective and feasible strategies for engagement of the private sector for effective case management and reporting (TB, malaria, HIV/AIDS, hepatitis) |  |  |

 |
| **3. PROJECT TITLE** (120 words) |
| Enter text here |
| **4. BACKGROUND AND RATIONALE** (1 page maximum. Literature review of previous studies on the subject; and justification of the study by stating the problem and its public health importance)  |
| Enter text here |
| **5. STUDY OBJECTIVES** (General and specific objectives. The latter should be SMART (Specific, Measurable, Achievable with the project’s budget and time, resourced (within the project’s budget), and time bound) |
| 5.1 Public health impact: please describe how the research will contribute the improved public health interventions and/or strengthen the public health system  |
| 5.2 Indicators and deliverables: please list the indicators related to each objectives and expected deliverables (at least 1 indicator and one expected result per objective) |
| Enter text here |
| **6. MATERIALS AND METHODS (**Describe the research methods that could best achieve the study objectives. These methods cover the items 5.1 to 5.7) |
| **6.1 Study area/setting** (Describe the area or setting where the study will be conducted. This description should cover the details relevant to the study topic) |
| Enter text here |
| **6.2 Study subjects** (Mention the eligibility criteria (inclusion and exclusion) of the study subjects) |
| Enter text here |
| **6.3 Study design** (Mention the type of study design eg cross-sectional, case-control, intervention study, etc..) |
| Enter text here |
| **6.4 Sample size** (Mention the input criteria for sample size estimation. This needs the expertise of an epidemiologist)  |
| Enter text here |
| **6.5 Sampling technique** (Mention the sampling technique that will be used in order to obtain a representative sample for your target population. This needs the expertise of an epidemiologist) |
| Enter text here |
| **6.6 Sampling technique** (Mention the sampling technique that will be used in order to obtain a representative sample for your target population. This needs the expertise of an epidemiologist) |
| Enter text here |
| **6.7 Data Collection methods, instruments used, measurements** 6.7.1 Describe the instruments used for data collection (questionnaire, observation recording form, etc..); studied variables included in these instruments, as well as the methods used to test for the validity and reliability of the instrument6.7.2 Techniques used should be briefly described and referenced6.7.3 Describe the quality control measures and good practices followed during the study implementation e.g. GLP, GCP, Laboratory quality assurance methods, etc.6.7.4 List study definitions (e.g. case definition)  |
| Enter text hereEnclose the data collection form (Annex 1) |
| **6.8 Data quality assurance methods, data management and analysis plans** (Describe the data quality assurance methods, data management and analysis plans, tests used for data analysis and statistical package(s) used) |
| Enter text here |
| **7. Ethical considerations** |
| All research proposals submitted to WHO must adhere to ethical conduct. This commitment will be ensured by the WHO/EMRO Selection Committee. The principal investigators are required to get clearance from a national, institutional or any other official Ethical Review Committee before submitting the proposals. Litigation involving human research has must be accompanied by a copy of ethical clearance certification and the informed consent document.*Please respond to the following questions:*1. Does this research involve human subjects? Yes € No €2. Is there a research ethics committee in your institution that reviews human subject research? Yes € No €3. If yes, have you received an ethical approval for this research? Yes € No €4. If you do not think that ethical clearance is needed for your study, please explain why not?----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------5. Is written informed consent from human subjects needed in this research? Yes € No €If no, please explain why?----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------*If yes, please attach a copy of the informed consent form that will be used in your research***Annex 2**6. Shall confidentiality of the information (e.g. medical records, Yes € No €biological samples) obtained from subjects be protected in this research? 7. Have you received any training on ethics of biomedical research? Yes € No € |
| **8. Bibliographic references** (List at least 10 recent articles relevant to the study subject and enumerated according to their order of appearance in the text)  |
| Enter text here |
| **9. Work plan** (Timelines of implementation of different activities, and monitoring and evaluation plan. It is preferable to use the MS project to develop the work plan) |
| Annex 3 |
| **10. Budget**  |
| Annex 4-Please distribute the budget by deliverables (see section 5.2) |
| **11. Risks and mitigation actions**  |
| Enter text here  |
| **12. Products**  |
| -Progress technical and financial reports: Halfway implementation of the project (6th month)-Final technical and financial reports: at the end of the project’s life (end of the year) |
| **13. Dissemination of results**  |
| -Describe how results will be disseminated-Copies of peer reviewed publications in indexed journals should be submitted to WHO. Researchers are requested to include a short financial support acknowledgement in the published articles. -The publications resulting from the supported projects and data will follow the **open-access policy**. **Principal investigator’s consent to provide copies of the peer reviewed publications originating from the supported project to WHO, to acknowledge the WHO financial support and to agree on making the articles and data open-access:**Signature of the principal investigator: -------------------------------------------------------  |
|  |

**Annexes**

*Annex 1. Data collection form*

*Annex 2. Informed Consent form*

*Annex 3. Work plan*

*Annex 4. Budget*

**Annex 3. Work plan**

(Please add the month’s name, and adapt activities according to your project)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Activities**  | **M1** | **M2** | **M3** | **M4** | **M5** | **M6** | **M7** | **M8** | **M9** | **M10** | **M11** | **M12** |
| **Finalization of the protocol and data collection tools**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Sampling of facilities**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Training**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Field work preparation**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Implementation**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Monitoring and evaluation missions** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Progress report** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Data collection, entry**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Data quality assurance**  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Data management and analysis** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Final report** |  |  |  |  |  |  |  |  |  |  |  |  |

**Annex 4. Budget**

|  |  |  |
| --- | --- | --- |
| **Project Title:** |   |  |
| **Currency: USD** |   |   | **Quantity** | **Total Budget** |
| **Category** | **Components** | **Unit Price** | **Q1** | **Q2** | **Q3** | **Q4** | **Total Quantity** |
|  |  |  |  |  |  |  |  |  |
| **1. Capacity building** | 1.1 National level training workshop |  |  |  |  |  |  |  |
| 1.2 International Consultant WHO |  |  |  |  |  |  |  |
| **2. Equipment and supplies**  |  2.1 Laboratory tests |  |  |  |  |  |  |  |
|  | 2.2 Reagents  |  |  |  |  |  |  |  |
| **3. Field work** | 3.1 Salaries |  |  |  |  |  |  |  |
| 3.2Per diem |  |  |  |  |  |  |  |
| 3.3 Data collection fees |  |  |  |  |  |  |  |
| 3.4 Internal travel (air travel) |  |  |  |  |  |  |  |
| 3.5 Maintenance of vehicles |  |  |  |  |  |  |  |
| 3.6 Vehicles rent or lease |  |  |  |  |  |  |  |
| **4. M&E**  | 4.1 Meetings |  |  |  |  |  |  |  |
| 4.2 Supervision |  |  |  |  |  |  |  |
| 4.3 International mission(s) |  |  |  |  |  |  |  |
| **5. Data entry**  | Per diem |  |  |  |  |  |  |  |
| **6. Data quality audit and data management** | Salary/per diem |  |  |  |  |  |  |  |
| **7. Data analysis** | Salary/ per diem |  |  |  |  |  |  |  |
| **8. Report writing** | Supervision at the facility level (POL) |  |  |  |  |  |  |  |
| **Modify or add as per your project**  |

1. Surgery, Antibiotics, Facial cleanliness, and Environment improvement [↑](#footnote-ref-1)
2. Key populations: IDU (intravenous drug users), MSM (men having sex with men), CSW (commercial sex workers), prisoners, trans-gender, etc. [↑](#footnote-ref-2)